Please login to the form below

tropical diseases

This page shows the latest tropical diseases news and features for those working in and with pharma, biotech and healthcare.

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access. The FDA has given its seal of approval to Novartis’ Egatan, which becomes the first approved treatment in the US for tropical disease fascioliasis. ... said Dr Mwelecela Malecela, Director of the

Latest news

Pfizer signs mRNA flu vaccine deal with BioNTech

number of diseases, including Zika and rabies. ... Last year, a research team from the University of Munich’s Department of Infectious Diseases and Tropical Medicine moved a rabies vaccine developed by CureVac into what it said was the
The power of pharma businesses to drive social change

For example, we have a focus on, and commitment to, combatting neglected tropical diseases (NTDs). ... Our research teams are collaborating with peers from organisations around the world to help in the development of effective treatments for diseases
Novartis' Swiss head of operations reveals job cuts

and said it planned to move its tropical diseases research from Singapore to California.
Sanofi pays $245m for FDA priority review voucher

Gilead Sciences bought one from Canada's Knight Therapeutics last year that was awarded by the FDA in return for developing a drug for a neglected tropical disease. ... The rising price also reflects the scarcity of the vouchers, which so far are only
GSK tops pharma access to medicines table

drive to tackle neglected tropical diseases," commented ATMI founder and chief executive Wim Leereveld. ... the pipeline tackling diseases affecting developing countries to 327 at last count.

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Reaching new heights

The seemingly intractable problems of neglected tropical diseases, compounded by poverty and war in Africa, finally appear to be responding to philanthropy-funded research and engagement, resulting in fundamental changes by ... biologics. Patients will
Pharma deals in August 2015

$65m. Antisense oligonucleotides target RNA and the new collaboration will extend into renal diseases, cardiovascular and metabolic fields. ... Introduced by the FDA in 2007, a priority review voucher (PRV) is an incentive for companies to invest in
Pharma deals during November 2014

from ten months down to six). Introduced by the FDA in 2007, a PRV is an incentive for companies to invest in treatments for neglected tropical diseases. One of 16 tropical ... diseases that qualify is leishmaniasis, for which Knight's Impavido
Interview: Charles Mgone, EDCTP

We will ask them what areas they are interested in regarding our scope in HIV, TB, malaria and now neglected tropical diseases.”. ... EDCTP offers a more cost-effective and unified means of tackling poverty-related diseases.”.